Cargando...
PHASE I TRIAL OF A BIVALENT GANGLIOSIDES VACCINE IN COMBINATION WITH β-GLUCAN: FOR HIGH-RISK NEUROBLASTOMA IN SECOND OR LATER REMISSION
BACKGROUND: To report on a phase I trial designed to find the maximally tolerated dose in children of the immunological adjuvant OPT-821 in a vaccine containing neuroblastoma-associated antigens (GD2 and GD3) (Clinicaltrials.gov NCT00911560). Secondary objectives were to obtain preliminary data on i...
Guardado en:
| Publicado en: | Clin Cancer Res |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5592799/ https://ncbi.nlm.nih.gov/pubmed/24520094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1012 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|